- AU$2.51bn
- AU$2.52bn
- $17.20m
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M
Brief: Mesoblast Posts HY Total Revenues $51.3 Million
Brief: Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million
Brief: Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-Agvhd
Brief: Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L
Brief: Mesoblast Says Ryoncil Sales For Quarter Increase 60% To $35.1M
ASX-shares of Mesoblast rise on strong Ryoncil sales
Brief: Mesoblast Appoints Philip Facchina As Non-Executive Chair
Brief: Mesoblast Expects Gross Revenue Of More Than $30.0 Mln From Sales Of Ryoncil For Quarter Ending Dec 31
Brief: Mesoblast Says James M. O’Brien Appointed Chief Financial Officer
Brief: Mesoblast Appoints James M. O'brien As U.S.-Based CFO
Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division
Brief: Mesoblast To Meet With FDA Next Month To Discuss Rexlemestrocel-L And Opioid Cessation
ASX shares of Mesoblast jump on FDA meeting plans, Phase 3 study update
Brief: Mesoblast Posts Quarter Revenue From Cell Therapy Products $20.6 Million
ASX-listed Mesoblast hits 8-month high; Bell Potter upbeat on Ryoncil revenues